The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Molecular Biology of the Androgen Receptor
Abstract
Androgen receptor (AR) is a member of the steroid hormone receptor family of molecules. AR primarily is responsible for mediating the physiologic effects of androgens by binding to specific DNA sequences that influence transcription of androgen-responsive genes. The three-dimensional structure of the AR ligand-binding domain has shown it is similar to other steroid hormone receptors and that ligand binding alters the protein conformation to allow binding of coactivator molecules that amplify the hormone signal and mediate transcriptional initiation. However, AR also undergoes intramolecular interactions that regulate its interactions with coactivators and influence its activity. A large number of naturally occurring mutations of the human AR gene have provided important information about AR molecular structure and intermolecular interactions. AR is also a critical mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the natural history of the disease. Late-stage prostate cancer, unresponsive to hormonal deprivation, sustains AR signaling through a diverse array of molecular strategies. Variations in the AR gene may also confer genetic predisposition to prostate cancer development and severity. Further understanding of AR action and new strategies to interfere with AR signaling hold promise for improving prostate cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
Luisi, B. F., Xu, W. X., Otwinowski, Z., Freedman, L. P., Yamamoto, K. R., & Sigler, P. B. (1991) · Nature · doi:10.1038/352497a0 · Cited by 1,503
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Research works printed but not linked: 26
- 10.1677/jme.0.0020001 · doi:10.1677/jme.0.0020001
- 10.1002/1097-4547(20001115)62:4<547::AID-JNR9>3.0.CO;2-G · doi:10.1002/1097-4547(20001115)62:4<547::aid-jnr9>3.0.co;2-g
- 10.1021/bi00252a027 · DOI
- 10.1210/endo-128-1-349 · doi:10.1210/endo-128-1-349
- 10.1210/endo.131.3.1324158 · doi:10.1210/endo.131.3.1324158
- Lindzey J, Grossmann M, Kumar MV, et al: Regulation of the 5′-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 7: 1530,1993-1540, · doi:10.1210/mend.7.12.7511785
- 10.1007/PL00006391 · DOI
- 10.1042/bj3410515 · DOI · Paper page
- 10.1210/mend.13.12.0396 · doi:10.1210/mend.13.12.0396 · Paper page
- 10.1210/mend.12.4.0089 · doi:10.1210/mend.12.4.0089 · Paper page
- 10.1210/mend.11.6.0009 · doi:10.1210/mend.11.6.0009 · Paper page
- 10.1038/25931 · DOI · Paper page
- 10.1210/mend.12.8.0153 · doi:10.1210/mend.12.8.0153 · Paper page
- 10.1016/0304-3835(91)90181-G · doi:10.1016/0304-3835(91)90181-g
- 10.1038/bjc.1979.122 · doi:10.1038/bjc.1979.122
- 10.1002/1097-0142(19811115)48:10<2267::AID-CNCR2820481023>3.0.CO;2-R · doi:10.1002/1097-0142(19811115)48:10<2267::aid-cncr2820481023>3.0.co;2-r
- 10.1016/0022-4731(82)90572-6 · doi:10.1016/0022-4731(82)90572-6
- 10.1016/S0022-5347(17)41518-7 · doi:10.1016/s0022-5347(17)41518-7
- 10.1016/S0022-5347(17)50871-X · doi:10.1016/s0022-5347(17)50871-x
- 10.1002/1097-0142(19870501)59:9<1599::AID-CNCR2820590913>3.0.CO;2-V · doi:10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v
- Rennie PS, Bruchovsky N, Goldenberg SL: Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 11: 513,1988-517, (suppl 2) · doi:10.1097/00000421-198801102-00004
- Castellanos JM, Galan A, Calvo MA, et al: Predicting response of prostatic carcinoma to endocrine therapy. Lancet 1: 448,1982 (letter) · doi:10.1016/s0140-6736(82)91645-2
- 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7 · doi:10.1002/(sici)1097-0045(20000515)43:3<225::aid-pros9>3.0.co;2-7
- 10.1002/(SICI)1096-9896(199912)189:4<559::AID-PATH471>3.0.CO;2-Y · doi:10.1002/(sici)1096-9896(199912)189:4<559::aid-path471>3.0.co;2-y
- 10.1007/978-1-4613-1267-3_12 · DOI
- 10.1210/mend.11.4.9906 · doi:10.1210/mend.11.4.9906 · Paper page
Cited by
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Hu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Human prostate cancer risk factors
Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., et al. (2004) · Cancer · doi:10.1002/cncr.20408 · Cited by 650
Androgen receptor signaling in prostate cancer development and progression
Tindall, D., & Lonergan, P. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 535
Sex differences in lipid and lipoprotein metabolism
Palmisano, B. T., Zhu, L., Eckel, R. H., & Stafford, J. M. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.05.008 · Cited by 522
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
The influence of sex and gender on the immune response
Oertelt-Prigione, S. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.11.022 · Cited by 459
Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Kinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
Taplin, M., & Balk, S. P. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10653 · Cited by 390
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
AR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
Xu, Y., Chen, S.-Y., Ross, K. N., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4472 · Cited by 301
Kraemer, W. J., Ratamess, N. A., Hymer, W. C., Nindl, B. C., & Fragala, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00033 · Cited by 300
He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
Molecular cell biology of androgen receptor signalling
Bennett, N. C., Gardiner, R. A., Hooper, J. D., Johnson, D. W., & Gobe, G. C. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.11.013 · Cited by 292
Li, L., Ren, C. H., Tahir, S. A., Ren, C., & Thompson, T. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9389-9404.2003 · Cited by 291
Gao, N., Zhang, J., Rao, M. A., Case, T. C., Mirosevich, J., Wang, Y., Jin, R., Gupta, A., Rennie, P. S., & Matusik, R. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0020 · Cited by 279
Jung, M. E., Ouk, S., Yoo, D., Sawyers, C. L., Chen, C., Tran, C., & Wongvipat, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901488g · Cited by 266
Alimirah, F., Chen, J., Basrawala, Z., Xin, H., & Choubey, D. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.041 · Cited by 265
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 258
Chmelar, R., Buchanan, G., Need, E. F., Tilley, W., & Greenberg, N. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22365 · Cited by 255
Roles and regulation of Wnt signaling and β-catenin in prostate cancer
Verras, M., & Sun, Z. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.06.004 · Cited by 180
Wright, M. E., Tsai, M.-J., & Aebersold, R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0031 · Cited by 166
Yang, M., Xie, W., Mostaghel, E., Nakabayashi, M., Werner, L., Sun, T., Pomerantz, M., Freedman, M., Ross, R., Regan, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2405 · Cited by 159
McEwan, I. J. (2004) · Endocrine-related cancer · doi:10.1677/erc.0.0110281 · Cited by 156
Role of sex steroid receptors in pathobiology of hepatocellular carcinoma
Kalra, M., Mayes, J., Assefa, S., Kaul, A. K., & Kaul, R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5945 · Cited by 141
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Castration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Brooke, G. N., Parker, M. G., & Bevan, C. L. (2008) · Oncogene · doi:10.1038/sj.onc.1210955 · Cited by 79
“The AR is a member of the nuclear receptor superfamily and shares their common domain structure including two activation functions – AF1 in the N-terminus and AF2 in the C-terminal ligand-binding domain (LBD) (Gelmann, 2002).”
BackgroundInfluentialEftekharzadeh, B., Banduseela, V. C., Chiesa, G., Martínez-Cristóbal, P., Rauch, J. N., Nath, S. R., Schwarz, D. M. C., Shao, H., Marin-Argany, M., Di Sanza, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11594-y · Cited by 76
The novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., & Burnstein, K. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0158 · Cited by 67
Decreased Androgen Receptor Gene Methylation in Premature Pubarche: A Novel Pathogenetic Mechanism?
Vottero, A., Capelletti, M., Giuliodori, S., Viani, I., Ziveri, M., Neri, T. M., Bernasconi, S., & Ghizzoni, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2354 · Cited by 58
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Expression of the Muscle Atrophy Factor Muscle Atrophy F-Box Is Suppressed by Testosterone
Zhao, W., Pan, J., Wang, X., Wu, Y., Bauman, W. A., & Cardozo, C. P. (2008) · Endocrinology · doi:10.1210/en.2008-0664 · Cited by 49
Dubbink, H. J., Hersmus, R., Pike, A. C. W., Molier, M., Brinkmann, A. O., Jenster, G., & Trapman, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0348 · Cited by 47
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/9649838 · Cited by 14
“In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12 [28, 29].”
Background
Metadata
- Authors
- Gelmann, E. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-07-01
- Volume
- 20
- Issue
- 13
- Pages
- 3001-3015
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125069527
- Cited by
- 942
- References
- 174
- FWCI
- 34.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.